In addition, we show that the fusion antigens can elicit tumor-specific CD8+ cytotoxic T lymphocytes when formulated with CpG and Alum adjuvants, and enhance CD8+ T cells and NK cells' infiltrating into tumor. The gene discussed is CD8A; the disease is neoplasm.